Showing 751-760 of 1601 results for "".
- Get In First: A Derm's Case for Early Psoriasis Treatmenthttps://practicaldermatology.com/news/from-aad-2025-a-case-for-early-psoriasis-treatment/2471544/Addressing psoriasis early in its course may lead to prolonged remission and better outcomes, and dermatologists should take note, according to a presentation at the 2025 American Academy of Dermatology Annual Meeting in Orlando.
- ICONIC-LEAD: Icotrokinra Clears Almost Half of Psoriasis Patients in Phase 3 Trialhttps://practicaldermatology.com/news/iconic-lead-icotrokinra-clears-almost-half-of-psoriasis-patients-in-phase-3-trial/2471543/Nearly half of patients with moderate-to-severe plaque psoriasis treated with icotrokinra achieved completely clear skin at week 24, according to new data presented at the 2025 America Academy of Dermatology Annual Meeting. The
- Martha Stewart Describes Neurotoxin Preferenceshttps://practicaldermatology.com/news/martha-stewart-describes-neurotoxin-preferences/2471541/BOTOX Cosmetic’s platysma bands indication has a fan in Martha Stewart. The keynote speaker at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, said she visits her dermatologist “once every couple months.” Gesturing to her jaw and neck, Stewart said she ge
- Almirall Presents Early-Stage Pipeline Progress for Tirbanibulinhttps://practicaldermatology.com/news/Almirall-Presents-Early-Stage-Pipeline-Progress-Tirbanibulin/2471540/Almirall, S.A. presented five scientific posters at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, including new data on tirbanibulin, a topical treatment for actinic keratosis (AK), and progress of its early-stage asset LAD191, a high-affinity monoclonal antib
- AAD Posters Highlight Positive Data for Roflumilasthttps://practicaldermatology.com/news/AAD-Posters-Highlight-Positive-Data-Roflumilast/2471539/Arcutis Biotherapeutics, Inc., announced new data from two posters shared at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. The first poster presentation details the positive efficacy, patient-reported outcomes, and tolerability for the use of once-daily
- Lebrikizumab Achieves Deep and Sustained Response at 3 Years in ADhttps://practicaldermatology.com/news/Lebrikizuab-Achieves-Deep-Sustained-Response-3-Years-AD/2471538/Lebrikizumab (EBGLYSS) achieved deep and sustained response for patients with moderate-to-severe atopic dermatitis (eczema) at 3 years in the ADjoin long-term extension study presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, Eli Lilly and Company anno
- Topical Gel Bimiralisib Shows Promise for AK in Interim Resultshttps://practicaldermatology.com/news/Topical-Gel-Bimiralisib-Shows-Promise-AK-Interim-Results/2471537/Interim results from an ongoing Phase 2 clinical trial in actinic keratosis highlighted strong potential for the safety and efficacy of topical gel bimiralisib, a selective pan-PI3K/mTOR inhibitor, Torqur AG announced at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Fl
- JAK Inhibitors, Low-Dose Naltrexone Touted as New Options for Nail Lichen Planushttps://practicaldermatology.com/news/JAK-Inhibitors-Low-Dose-Naltrexone-Touted-New-Options-Nail-Lichen-Planus/2471532/JAK inhibitors and low-dose naltrexone appear to be two game-changing options for treatment of nail lichen planus, Shari Lipner, MD, PhD, FAAD, said at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida. Dr. Lipner noted the activity of the JAK pathway in lic
- Molluscum Contagiosum: Old Condition, Same Challengeshttps://practicaldermatology.com/news/molluscum-contagiosum-old-condition-same-challenges/2471528/Molluscum contagiosum has been studied and treated for almost two centuries, and while modern therapies are helping patients obtain better outcomes, some aspects of managing and treating the disease remain challenging At the 2025 American Academy of Dermatology (AAD) Annual Meeting, Dr. Ad
- AI Highlighted as Potential Game-Changer for GPP, HShttps://practicaldermatology.com/news/AI-Highlighted-Potential-Game-Changer-GPP-HS/2471522/Diagnosing and efficiently treating rare diseases in dermatology has long been an important challenge, and one session at the 2025 American Academy of Dermatology (AAD) Annual Meeting highlighted how artificial intelligence (AI) can help. “Using Artificial Intelligence for Rare Dermatolog